<?xml version="1.0" encoding="UTF-8"?>
<p>A case series reported four Italian patients with moderate-to-severe unstable COVID-19 infections. Except one female nurse, the other three male individuals were aged 51–76 with high body mass index, and two of them had chronic obstructive pulmonary disease plus hypertension histories. Under baricitinib 2 mg or 4 mg for 10–12 days, all patients improved in clinical symptoms (fever, cough, and dyspnea) and in laboratory data [interleukin-6 (IL-6), C-reactive protein, ferritin, liver enzymes, 
 <italic>D</italic>-dimer, and viral loads].
 <sup>
  <xref rid="bibr13-1759720X20947296" ref-type="bibr">13</xref>
 </sup>
</p>
